Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Allergan Ophthalmic Products Spin-Off Creates $500 Mil. Device Company

This article was originally published in The Gray Sheet

Executive Summary

Advanced Medical Optics' plan to develop a phakic intraocular lens (IOL) based on Ophtec BV's Artisan lens technology exemplifies the types of strategic alliance to be highlighted by AMO following its spin-off from Allergan in July

You may also be interested in...



Allergan Eyes Edema, Macular Degeneration Indications With Oculex Buy

Allergan could enter the retinal therapy market in late 2006 with Oculex' macular edema implant Posurdex, following its $230 mil. acquisition of the tech firm

Allergan Eyes Edema, Macular Degeneration Indications With Oculex Buy

Allergan could enter the retinal therapy market in late 2006 with Oculex' macular edema implant Posurdex, following its $230 mil. acquisition of the tech firm

Ophthalmic Spin-Offs Alcon, AMO See Stock Gains In 2002, Join MDDI Index

Ophthalmic device makers Alcon and Advanced Medical Optics (AMO) were both able to achieve double-digit stock price percentage gains in 2002 after debuting as independent firms, in part due to expanding sales of surgical products such as IOLs

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT015996

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel